checkAd

    LA JOLLA PHARMACEUTICAL - 500 Beiträge pro Seite

    eröffnet am 15.09.00 15:39:43 von
    neuester Beitrag 02.10.00 15:08:44 von
    Beiträge: 5
    ID: 243.889
    Aufrufe heute: 0
    Gesamt: 274
    Aktive User: 0


     Durchsuchen

    Begriffe und/oder Benutzer

     

    Top-Postings

     Ja Nein
      Avatar
      schrieb am 15.09.00 15:39:43
      Beitrag Nr. 1 ()
      bin an LA JOLLA PHARMACEUTICAL interessiert.

      Hat jemand nähere Informationen ?

      WKN: 898844
      US Kürzel: LJPC

      Danke
      B1B2 :)
      Avatar
      schrieb am 15.09.00 16:03:55
      Beitrag Nr. 2 ()




      La Jolla Pharmaceutical Company develops disease-specific therapeutics using its proprietary Tolerance Technology® for the treatment of life-threatening antibody-mediated diseases such as lupus, antibody-mediated thrombosis and antibody-mediated organ rejection in xenotransplantation. Current therapies for these disorders only address symptoms or nonspecifically suppress the normal operation of the immune system, which often results in severe, adverse side effects and hospitalization. The company has completed a Phase II/III trial of its lupus drug candidate, LJP 394, with positive efficacy results for patients whose antibodies have high affinity for the drug. LJP 394 is designed to specifically reduce the levels of antibodies to double-stranded DNA that are associated with lupus nephritis, a principal cause of morbidity and mortality in lupus patients. To date, the Company has conducted five clinical trials where targeted antibodies were reduced after treatment with LJP 394. The Company plans to begin a Phase III trial with this compound later this year. Lupus is believed to afflict about 1,000,000 people in the United States, Europe and Japan.
      La Jolla Pharmaceutical uses its proprietary Tolerance Technology to design novel therapeutic molecules to shut down faulty B cells and arrest their production of disease-causing antibodies without suppressing the healthy functions of the immune system. Toleragens® consist of multiple copies of B-cell epitopes attached to a carrier platform. These molecules bind to antibodies on the surface of a B cell to induce anergy and apoptosis. Toleragens can be constructed with epitopes made of nucleic acids, peptides or carbohydrates to target virtually any pathogenic antibody. The Company owns 87 issued or granted patents and has 52 patent applications pending.
      Avatar
      schrieb am 15.09.00 17:28:06
      Beitrag Nr. 3 ()
      8,86$ +4,23% Umsatz: 17900
      Avatar
      schrieb am 15.09.00 21:41:04
      Beitrag Nr. 4 ()
      ljpc ist ein hochspekulativer, hochvolatiler und enger wert.
      liegt bei mir nur als beimischung seit feb.00.
      die firma wird wahrscheinlich nie eine große rolle bei den biotechs spielen, selbst, wenn die mal ein medikament aufm markt bringen.
      eher wahrscheinlich ist da schon eine übernahme durch millenium ph. oder so (ähnlich wie bei leukosite).
      das wär das beste, was ljpc mittel-langfristig passieren könnte...

      gruß
      Avatar
      schrieb am 02.10.00 15:08:44
      Beitrag Nr. 5 ()
      Monday October 2, 8:23 am Eastern Time
      Press Release

      La Jolla Pharmaceutical Presents At the UBS Warburg Global Life Sciences Conference

      NEW YORK--(BW HealthWire)--Oct. 2, 2000--La Jolla Pharmaceutical Co. (Nasdaq:LJPC - news) announced today that its Chairman & Chief Executive Officer, Steven B. Engle, presented an overview of the company`s recently initiated Phase III clinical trial of its lupus drug candidate, LJP 394, at the UBS Warburg Global Life Sciences Conference in New York City.
      ¶ Engle reported that more than 10 clinical sites have been

      initiated and that the first patient has been dosed.

      ``We are pleased that the initiation of our Phase III clinical trial is proceeding on schedule,`` said Engle. ``We plan to have more than 50 sites in North America enrolling patients by the end of the year and then expect to add about 15 more sites across Europe early next year.``

      La Jolla Pharmaceutical Co. (LJP) is a San Diego-based biotechnology company developing therapeutics for antibody-mediated diseases, such as lupus and stroke, which afflict several million people in the United States and Europe. The company is also developing drugs for antibody-mediated stroke, heart attack, and deep-vein thrombosis, for xenotransplantation, and for other antibody-mediated diseases.

      La Jolla Pharmaceutical`s drug candidates, known as Toleragens® are designed to arrest the production of disease-causing antibodies without suppressing the healthy functions of the immune system. In five human clinical trials, its Tolerance Technology® platform has been shown to reduce targeted disease-causing antibodies in lupus patients. The company`s common stock trades on The Nasdaq Stock Market under the symbol LJPC. For more information about the company, visit our Web site: www.ljpc.com.

      Except for historical statements, this press release contains forward-looking statements, including without limitation statements regarding the analysis of results from preclinical and clinical studies as well as La Jolla Pharmaceutical`s drug candidates and drug development plans. These forward-looking statements involving risks and uncertainties, and a number of factors, both foreseen and unforeseen, could cause actual results to differ materially from those anticipated. Clinical results for LJP 394 are derived from a trial that was terminated prior to completion, and certain data are incomplete. Future analyses of clinical trial results may not necessarily support conclusions to date. The company`s blood test to measure binding affinity for LJP 394 is experimental and has not been validated by independent laboratories. Tolerance, or the specific inactivation of pathogenic B cells, is a new technology that has not been proven. The company`s ability to develop and sell its products in the future may be affected by the intellectual property rights of third parties. Future clinical trials of the company`s drug candidates may have negative or inconclusive results. Future clinical trials of the company`s drug candidates may not support results of preclinical or other prior trials and pre IND studies of the company`s new candidate for treating antibody-mediated thrombosis may reveal a potential safety issue requiring the development of a new candidate. Any delays in testing of the company`s drug candidates and/or termination of development by the company would result in delays or lack of government approval to market the compound. The development of drug candidates involves many risks and uncertainties, including, without limitation, whether the drug can provide a meaningful clinical benefit, and any positive results observed to date may not be indicative of future results. La Jolla Pharmaceutical`s other potential drug candidates, including its Toleragen candidate for xenotransplantation, which have not progressed to clinical trials, involve comparable risks. Interested parties are urged to review the risks detailed from time to time in La Jolla Pharmaceutical Co.`s Securities and Exchange Commission (SEC) filings, including the report on Form 10-K for the year ended Dec. 31, 1999 and in Form 10-Q for the quarter ended June 30, 2000.


      Beitrag zu dieser Diskussion schreiben


      Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
      Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie
      hier
      eine neue Diskussion.
      LA JOLLA PHARMACEUTICAL